02 Jul 2015

Rocephin vials (Ceftriaxone) - United Kingdom

Rocephin vials

Last Updated on 02 Jul 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Rocephin vials Indication

Rocephin is indicated for the treatment of the following infections in adults and children including term neonates (from birth):

Bacterial Meningitis

Community acquired pneumonia

Hospital acquired pneumonia

Acute otitis media

Intra-abdominal infections

Complicated urinary tract infections (including pyelonephritis)

Infections of bones and joints

Complicated skin and soft tissue infections



Bacterial endocarditis

Rocephin may be used:

For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults

For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age.

For Pre-operative prophylaxis of surgical site infections

In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection

In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above

Rocephin should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum.

Consideration should be given to official guidelines on the appropriate use of antibacterial agents.


Rocephin vials Generic Name




Summary Product Characteristics (SPCs) Links
SPC - Rocephin 250mg, 1g and 2g vials (external site)

Related Learning Zones

Anti-Infectives Knowledge Network CDI

Anti-Infectives Knowledge Network CDI

The Anti-Infectives Knowledge Network – Clostridium difficile infection (AIKN-CDI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of thought leaders in the therapy area of anti-infectives, with a particular focus on C. difficile infection.

Recent updates include ECCMID, ICDS, EBMT and ISICEM 2015 slide decks and congress reports, an infographic on ‘CDI in the EU’, data from the largest ever European clinician consensus report, as well as congress overviews, news reports and CDI expert perspectives.

Anti-Infectives Knowledge Network IFI

Anti-Infectives Knowledge Network IFI

The Anti-Infectives Knowledge Network – Invasive Fungal Infections (AIKN-IFI), an initiative by Astellas Pharma EMEA, assembles the experience and expertise of a number of thought leaders in the area of anti-infectives, with a particular focus on invasive fungal infections.

This free resource is regularly updated with congress highlights, industry reports, policy changes, clinical guidelines and downloadable material from major medical events, so make sure you return often.

August 2015 MYC/15/0023/EUa

Rocephin vials Marketing Information

Rocephin vials Generic Name
Marketing Company
Roche Products Limited
Drug Type
Date of Issue, Marketing Authority 23/10/2003

Related Drugs - Infectious Diseases

Back to top